BLCO Bausch + Lomb Corporation

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Bausch + Lomb stock has delivered a 17.2% return over the past year, yet several valuation checks still flag the shares as cheap relative to an intrinsic value estimate and to market multiples. For investors, the puzzle is why a stock with a high value score and an intrinsic estimate that screens as undervalued is not pricing in more of that potential. The 17.2% 1 year return suggests Bausch + Lomb has already rewarded patient holders, but the move has not erased what some models see as a...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb (NYSE:BLCO) and its peers.

BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.

Bausch + Lomb (NYSE:BLCO) said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29. The company also reported

Bausch + Lomb (BLCO) said late Monday it plans to advance two of its pharmaceutical pipeline assets

Cooper Companies' 22% three-month surge reflects contact lens share gains, MiSight growth and a recovering fertility business.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months.

Revenue grew 8% while EBITDA surged 28%, driven by dry eye and surgical strength.

Cooper Cos. could get a pop from the sale of a surgical unit. What two activists are up to in the stock.

What Bausch + Lomb’s latest quarter tells you Bausch + Lomb (NYSE:BLCO) drew fresh attention after reporting second quarter 2026 earnings on 29 July, with higher revenue, a smaller net loss, and a modest increase to full year revenue guidance. For the quarter ended 30 June 2026, revenue was US$1.394b compared with US$1.278b a year earlier. The company reported a net loss of US$14m, which was smaller than the US$62m loss in the prior year period. Basic and diluted loss per share from...

BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue and EBITDA guidance after strong earnings.

Moby summary of Bausch + Lomb Corporation's Q2 2026 earnings call

Bausch Health Cos (NYSE:BHC) reported second-quarter results that management said extended its streak of revenue and adjusted EBITDA growth to 13 consecutive quarters, driven by performance in its Salix, international and Solta Medical businesses. For Bausch Health excluding Bausch + Lomb, second-q

Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said improved product mix, productivity initiatives and lower fixed-cost intensity suppor